Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Inclusion Criteria: 1. Male or female subjects aged ≥18 years old; 2. Locally advanced or metastatic non-squamous non-small cell lung cancer confirmed by histology or cytology (stage ⅢB-Ⅳ, according to the 8th Edition of the AJCC Staging system); 3. The tumour harbours one of the most common EGFR mutations (19del or L858R); 4. The programmed death-ligand 1 (PD-L1) tumoral expression is positive; 5. No previous systemic anti-tumor therapy for locally advanced or metastatic NSCLC; 6. According to RECIST 1.1, subjects have at least one measurable tumor lesion at baseline; 7. ECOG performance status score 0-2； 8. Subjects have voluntarily participated, signed and dated informed consent. Exclusion Criteria: 1. Lung squamous carcinoma (including adenosquamous carcinoma and undifferentiated carcinoma) and small cell lung cancer; 2. Subjects have no measurable tumor lesion at baseline; 3. Subjects with spinal cord compression or symptomatic brain metastases; 4. Subjects are suitable for surgery; 5. Previous therapy with platinum-based chemotherapy, EGFR-TKIs, or anti-PD1/PD-L1 agents; 6. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)\>2.5 × ULN, or serum total bilirubin (TBIL)\>1.5 × ULN, or Cr\>1.0×ULN; 7. Absolute value of neutrophil (ANC)\<1.5 × 109/L, or platelet (PLT) count\<75 × 109/L, or hemoglobin (HGB)\<90 g/L; 8. Any of the following disease within 12 months: myocardial infarction, severe/unstable stenocardia, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure, or cerebrovascular accident; 9. Women who are pregnancy or lactation, or fertile but not using contraception; 10. Suffering from other serious acute or chronic physical or mental problems; 11. Subjects who are considered ineligible for the study for other reasons according to the investigator's assessment.